Biogen, Biogen Completes Acquisition of Apellis Pharmaceuticals (2026) is a certified entry in Truverai's communication library, filed as a corporate communication of 3520 words. Its composite score is 91 out of 100.
From the communication: CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a l
Biogen's text was scored under the same locked configuration as every other entry in the library, which is what makes the 91 comparable to the rest. Truverai measures how a communication is presented, not whether the speaker was right, and it scores what was said rather than who said it.
This page needs JavaScript for the full interactive view. The summary above is the same information in plain HTML.